Exceptional response to everolimus in an NF1-deficient recurrent endometrioid adenocarcinoma: a case report - Top-Institutions - MDSpire

Exceptional response to everolimus in an NF1-deficient recurrent endometrioid adenocarcinoma: a case report

  • By

  • Maja Machulak

  • Magdalena Zwierzchowska

  • Kinga Łysak

  • Kamil Kośmider

  • Katarzyna Szklener

  • Magdalena Skórzewska

  • May 25, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology

  • #2

    National Cancer Center Hospital, Tokyo
    National Cancer Center Hospital, Tokyo

    Tokyo, Tokyo

    Key Differentiators

    • Oncology

  • #3

    Indiana University School of Medicine
    Indiana University School of Medicine

    Indianapolis, IN

    Key Differentiators

    • Oncology

  • #4

    Icahn School of Medicine
    Icahn School of Medicine

    New York, NY

    Key Differentiators

    • Oncology

  • #5

    Sunnybrook Health Sciences Centre
    Sunnybrook Health Sciences Centre

    Toronto, ON

    Key Differentiators

    • Oncology

Original Source(s)

Exceptional response to everolimus in an NF1-deficient recurrent endometrioid adenocarcinoma: a case report

  • by Maja Machulak, Magdalena Zwierzchowska, Kinga Łysak, Kamil Kośmider, Katarzyna Szklener, Magdalena Skórzewska

  • May 25, 2026

Related Content

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer